Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up3.020 +0.010 (+0.332%)
Others

12/01/2018 17:37

[I-bank focus]CS lifts Sino Biopharm (01177) to HK$18.4

[ET Net News Agency, 12 January 2018] Credit Suisse lifted its target price for Sino
Biopharmaceutical (01177) to HK$18.4 from HK$13.19, and maintained its "outperform"
rating.
The research house said CFDA approved Hepatitis B virus (HBV) indication of Qingzhong in
November 2017 as a Category 4 drug. Credit Suisse believes Tenofovir and Entecavir will
keep replacing other nucleoside analogues (NAs) in China and forecast Qingzhong to
generate Rmb130/210/830mn sales in 2018-20.
It sees 8% sales CAGR of company's hepatitis franchise driven by ramping up Qingzhong
sales and solid Runzhong growth (3% CAGR in the next three years).
The research house also estimated that Anlotinib will be approved and immediately
commercialised in 1Q 2018, and sales to ramp up to Rmb280/980/1,764mn in 2018-20 and to
peak at Rmb3.0 bn in 2023. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.